文献速递妇科

新西兰早期药物流产后自我评估随访与血β-hCG对照的随机对照试验

Mate Whenua—Follow‐Up After Early Medical Abortion in New Zealand: A Randomised Controlled Trial
RSS 订阅 · BJOG · 2026-10-26

这项在新西兰六家流产服务机构开展的多中心随机对照试验纳入732例接受早期药物流产的孕妇,比较低敏感尿妊娠试验自我评估与血清β-hCG随访。自我评估组的完整随访率显著更高(94.5%对67.4%),且成功流产比例也更高(89.0%对81.0%)。作者推荐早期药物流产后采用自我评估以改善随访。

要点

  • 早期药物流产后采用低敏感尿妊娠试验自我评估,完整随访率显著高于血β-hCG随访。
  • 自我评估组的成功流产比例更高,且未显示并发症增加。
  • 该随访方式可能有助于改善生殖健康公平性。

核心结论

  • 作者推荐早期药物流产后采用低敏感尿妊娠试验自我评估随访,以改善完整随访率。
  • 该随访策略在显示临床有效性和安全性的同时,可能有助于改善生殖健康公平性。

研究设计与样本

  • 多中心平行组随机对照试验,在Aotearoa新西兰六家流产服务机构开展。
  • 研究对象为接受早期药物流产的孕妇,共732例,按1:1随机分组并以中心分层。

主要发现

  • 自我评估组完整随访率高于血液检查组(94.5%对67.4%,p<0.001;RR 1.41,95%CI 1.30–1.52)。
  • 自我评估组成功早期药物流产比例更高(89.0%对81.0%,p=0.002;RR 1.10,95%CI 1.03–1.17)。
  • 自我评估组额外随访检查更多(17.3%对11.1%,p=0.017;RR 1.55,95%CI 1.08–2.24)。
  • 两组在避孕措施、额外就诊、社区处方和并发症方面均无统计学差异。

关键数值与推荐

  • 完整随访定义:能在6周内讨论随访检测结果。
  • 避孕措施比例:自我评估组61.0%对血液检查组56.0%(RR 1.09,95%CI 0.96–1.23)。
  • 额外就诊比例:自我评估组11.%对血液检查组10.3%(RR 1.06,95%CI 0.70–1.62)。
  • 社区处方比例:自我评估组4.4%对血液检查组5.2%(RR 0.85,95%CI 0.44–1.63)。
  • 并发症比例:自我评估组8.5%对血液检查组8.7%(RR 1.09,95%CI 0.96–1.23)。

临床怎么用

  • 早期药物流产后可用低敏感尿妊娠试验自我评估代替常规血清β-hCG随访。
  • 临床实施时需注意自我评估可能导致更多额外随访检查。

局限性

  • 原文报告一例持续活胎妊娠在孕早期后被检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Objective To evaluate self-assessment with low sensitivity urine pregnancy test versus comparative serum bhCG in women having early medical abortion (EMA) for the outcomes of complete follow-up and ongoing live pregnancy. Design Multi-centre parallel group randomised controlled trial. Setting Six abortion services in Aotearoa New Zealand. Population Pregnant women having EMA. Methods Participants were randomised on a 1:1 ratio, stratified by centre, to a follow up protocol, self-assessment, or blood tests. Chi-squared tests, relative risks, and absolute risk differences (with 95% confidence intervals) were calculated. Main Outcome Measures Primary outcome was complete follow-up (able to discuss follow-up test result within 6 weeks). Secondary outcomes were successful abortion; contraception; complications; and additional services. Results There were 732 participants. More participants in the self-assessment group had complete follow-up compared to the blood test group (94.5% vs. 67.4%, p < 0.001; relative risk (RR) 1.41 [95% confidence interval (CI) 1.30–1.52]). More participants in the self-assessment group had a successful EMA (89.0% vs. 81.0%, p = 0.002; RR 1.10 [95% CI: 1.03–1.17]) and more additional follow up investigations (17.3% vs. 11.1%, p = 0.017; RR 1.55 [95% CI: 1.08–2.24]). There were no differences between groups in contraception (61.0% vs. 56.0%; RR 1.09 [95% CI: 0.96–1.23]), additional health care visits (11.% vs. 10.3%; RR 1.06 [95% CI: 0.70–1.62]), community prescriptions (4.4% vs. 5.2%; RR 0.85 [95% CI: 0.44–1.63]) or complications (8.5% vs. 8.7%; RR 1.09 [95% CI: 0.96–1.23]). There was one ongoing live pregnancy detected after the first trimester. Conclusions The authors recommend self-assessment after EMA for improved follow-up. In addition to demonstrating clinical effectiveness and safety, the findings have important implications for improving reproductive health equity. Trial Registration Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12623000890639 (registered prospectively on 21/08/2023; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384373&isClinicalTrial=False)

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. BJOG:Mate Whenua—Follow‐Up After Early Medical Abortion in New Zealand: A Randomised Controlled Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。